We will continue to see increase in share of revenues in speciality business: CS Murlidharan, Sun Pharma

economictimes.indiatimes.com:

«As far as the global speciality sales in current quarter, Q1 FY24, we did U.S. dollar 232 million, which is about 20% growth over the previous year corresponding quarter. And if you look at our FY22-23 revenues of speciality business globally, it was $874 million, which is almost doubled over a period of three years,» says CS Murlidharan, CFO, Sun Pharma.The on ground situation largely with respect to pricing in the US, was there any improvement with regard to price erosion sequentially and what is the outlook going forward?As we have shared in the call the U.S.

general pricing is more of product specific. We have not seen any specific changes in overall trends or the commercial landscape continues to be dynamic.I also want to understand, how do you see the speciality sales going forward? What is the next focus area for the company and how do you see this contributing and increasing in terms of contribution from this?As far as the global speciality sales in current quarter, Q1 FY24, we did U.S. dollar 232 million, which is about 20% growth over the previous year corresponding quarter.

And if you look at our FY22-23 revenues of speciality business globally, it was $874 million, which is almost doubled over a period of three years. And we are well positioned in terms of our speciality business. And we will continue to see increase in share of revenues of speciality to the consolidated revenues.And the expectation with regard to India sales was actually higher. When I am looking at other pharma companies in the space, they are clocking better sales overall. What factors could you talk to us about with regard to Sun Pharma, were at play in Q1 and how should one look at the outlook going forward?So, quarterly sales growth in